A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy.
Department of Medical Oncology, Institut Bergonié, Bordeaux.
T
T
Grellety
Department of Pathology, Institut Bergonié, Bordeaux.
I
I
Soubeyran
INSERM U916, Institut Bergonié, University of Bordeaux, Bordeaux, France.
J
J
Robert
Department of Medical Oncology, Institut Bergonié, Bordeaux.
H
H
Bonnefoi
Department of Medical Oncology, Institut Bergonié, Bordeaux a.italiano@bordeaux.unicancer.fr.
A
A
Italiano
D015703:Antigens, CD; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D015820:Cadherins / Q000235:genetics*; D000069287:Capecitabine / Q000008:administration & dosage; D018275:Carcinoma, Lobular / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary; D005260:Female; D006801:Humans; D000077341:Lapatinib; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D020125:Mutation, Missense; D011799:Quinazolines / Q000008:administration & dosage; D011859:Radiography; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D016896:Treatment Outcome
D015703:Antigens, CD; D015820:Cadherins; D000069287:Capecitabine; D000077341:Lapatinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; C513384:CDH1 protein, human; C508053:ERBB2 protein, human